NCT00421590已完成2 期
A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and Pharmacodynamics of SMC021 (0.8 mg Salmon Calcitonin/200 mg 5-CNAC) in Healthy Postmenopausal Women
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- To assess the effect of concomitant antacid (calcium carbonate / magnesium hydroxide) on the pharmacokinetics and pharmacodynamics (decrease in serum CTX-I) of SMC021 (0.8 mg salmon calcitonin/200 mg 5-CNAC)
研究概览
简要总结
This study will assess the effect of concomitant antacid on the pharmacokinetics and pharmacodynamics of SMC021
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy postmenopausal female subjects, 40 to 70 years of age, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
- •At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed after the subject has rested for at least three (3) minutes. All blood pressure measurements at other time-points should be assessed with the subject seated, and utilizing the same arm for each determination.
- •Postmenopausal women must have no regular menstrual bleeding for at least 5 years prior to inclusion or must have been surgically sterilized at least 6 months prior to screening.
- •Body mass index (BMI) must be within the range of 18 to
- •Subjects must weigh at least 50 kg to participate in this study.
- •Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent.
排除标准
- •Smokers who report cigarette use of ≥ 5 cigarette per day. Smoking will not be allowed on the days of each dosing up to the last blood sampling or the last assessment.
- •Use of any prescription drugs or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) started within the last month prior to screening.
- •Participation in any clinical investigation within 4 weeks prior to dosing, or less than 10 times the corresponding half life of the drug taken.
- •The current or previous treatment that would affect bone metabolism/remodeling.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- •Subjects with a hemoglobin level equal to or below 7.5 mmol/L at screening.
- •Significant illness within two weeks prior to dosing.
- •A past medical history of clinically significant ECG abnormalities or a family history grandparents, parents and siblings) of a prolonged QT-interval syndrome.
- •History of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension, sinus arrhythmia).
- •History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated),
- •History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
- •Poorly controlled diabetes
- •History of malignancy of any organ system within the past 5 years
- •A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- •HIV positive
- •History of drug or alcohol abuse within the 12 months prior to dosing.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
To assess the effect of concomitant antacid (calcium carbonate / magnesium hydroxide) on the pharmacokinetics and pharmacodynamics (decrease in serum CTX-I) of SMC021 (0.8 mg salmon calcitonin/200 mg 5-CNAC)
次要结局
- To assess the tolerability of concomitantly-administered antacid and SMC021
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women VolunteersEmbryo TransferNCT02703181GlaxoSmithKline31
已完成
2 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic FibrosisCystic FibrosisNCT00506792Novartis Pharmaceuticals9
已完成
1 期
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®Healthy SubjectsNCT04027803Biocad78
已完成
1 期
First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy VolunteersHealthy VolunteersNCT01459562Swedish Orphan Biovitrum20
已完成
1 期
Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy SubjectsDyslipidemiaNCT01879020Mitsubishi Tanabe Pharma Corporation61